Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock Price

MDGLStock

$449.74+1.72%52W

Market Cap$10.39B

P/E—

PEG Ratio—

Div yield—

Beta-1.07

MDGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.24%

Price vs S&P 500 (4W)-12.51%

VGM Score54.85

Book Value / Share (Quarterly)$22.68

P/TBV (Annual)22.22x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.06

Price vs S&P 500 (YTD)-34.70%

Gross Margin (TTM)91.48%

Net Profit Margin (TTM)-25.32%

EPS (TTM)$-12.87

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$-12.87

EPS (Annual)$-12.85

ROI (Annual)-30.58%

Gross Margin (Annual)94.14%

Net Profit Margin (5Y Avg)-12793.16%

Cash / Share (Quarterly)$36.32

Revenue Growth QoQ (YoY)71.17%

ROA (Last FY)-22.89%

Revenue Growth TTM (YoY)149.04%

EBITD / Share (TTM)$-12.50

ROE (5Y Avg)-94.94%

Operating Margin (TTM)-25.34%

Cash Flow / Share (Annual)$-8.45

P/B Ratio19.84x

P/B Ratio (Quarterly)23.64x

Net Income / Employee (Annual)$-315,100

EV / Revenue (TTM)8.13x

Net Interest Coverage (TTM)-163.11x

ROA (TTM)-25.53%

EV / EBITDA (TTM)629.99x

EPS Incl Extra (Annual)$-12.85

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)2.76x

3-Month Avg Trading Volume0.33M

52-Week Price Return1.72%

Revenue / Employee (TTM)$1,403,200

Tangible BV / Share (Quarterly)$22.37

P/S Ratio (Annual)10.84x

Asset Turnover (Annual)0.76x

52-Week High$615.00

Operating Margin (5Y Avg)-12410.94%

EPS Excl Extra (Annual)$-12.85

CapEx CAGR (5Y)60.06%

Tangible BV CAGR (5Y)1.61%

26-Week Price Return-14.33%

Quick Ratio (Annual)3.62x

13-Week Price Return-18.74%

Total Debt / Equity (Annual)0.56x

Current Ratio (Quarterly)3.20x

Enterprise Value$10.44B

Asset Turnover (TTM)1.01x

Book Value / Share Growth (5Y)11.25%

Revenue / Employee (Annual)$1,047,400

Pretax Margin (Annual)-30.08%

Cash / Share (Annual)$43.06

3-Month Return Std Dev38.32%

Net Income / Employee (TTM)$-355,300

ROE (Last FY)-47.83%

Net Interest Coverage (Annual)-68.31x

EPS Basic Excl Extra (Annual)$-12.85

P/FCF (TTM)109.30x

Receivables Turnover (TTM)9.46x

Total Debt / Equity (Quarterly)0.65x

EPS Incl Extra (TTM)$-12.87

Receivables Turnover (Annual)10.18x

ROI (TTM)-35.56%

P/S Ratio (TTM)8.09x

Pretax Margin (5Y Avg)-12793.16%

Revenue / Share (Annual)$42.72

Tangible BV / Share (Annual)$26.06

Forward P/E148.08x

Price vs S&P 500 (52W)-13.81%

Year-to-Date Return-22.77%

5-Day Price Return-3.73%

EPS Normalized (Annual)$-12.85

ROA (5Y Avg)-59.17%

Net Profit Margin (Annual)-30.08%

Month-to-Date Return-10.76%

Cash Flow / Share (TTM)$-19.21

EBITD / Share (Annual)$-13.43

Operating Margin (Annual)-31.60%

LT Debt / Equity (Annual)0.56x

ROI (5Y Avg)-79.76%

LT Debt / Equity (Quarterly)0.65x

EPS Basic Excl Extra (TTM)$-12.87

P/TBV (Quarterly)23.97x

P/B Ratio (Annual)21.94x

Inventory Turnover (TTM)1.34x

Pretax Margin (TTM)-25.32%

Book Value / Share (Annual)$26.39

Price vs S&P 500 (13W)-21.43%

Beta-1.07x

P/FCF (Annual)417.81x

Revenue / Share (TTM)$44.05

ROE (TTM)-56.65%

52-Week Low$393.61

vGradeD

gGradeA

mGradeC

vgmGradeC

MDGL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$2.23	-$1.99	+10.76%(+$0.24)
Q1 2026	May 6, 2026	-$4.14	-$1.38	+66.70%(+$2.76)
Q4 2025	Feb 19, 2026	-$0.88	-$2.57	-192.20%(-$1.69)
Q3 2025	Nov 4, 2025	-$1.99	-$4.96	-148.77%(-$2.96)
Q2 2025	Aug 5, 2025	-$3.53	-$1.90	+46.21%(+$1.63)

MDGL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.09

4.08

4.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Madrigal Pharmaceuticals, Inc. Common Stock

Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor beta agonist designed to address the underlying causes of MASH and prevent progression to cirrhosis and liver failure.

MDGL Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.09

Revenue estimate$406.28M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

MDGL Insider Transactions

SellSep 11, 2026
SIBOLD WILLIAM JOHN
Chief Executive Officer
Shares: 11,583Value: $6.24M
SellAug 17, 2026
KELLEY SHANNON T
General Counsel
Shares: 664Value: $341,940

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

TECHBio-Techne Corp.Biological Products
ALBAlbemarle CorporationPlastics & Resins
RGENRepligen CorpBiological Products
CLXClorox CompanyCleaning & Polishing Products
APGEApogee Therapeutics, Inc. Common StockBiological Products
PCVXVaxcyte, Inc. Common StockBiological Products
IBRXImmunityBio, Inc. Common StockBiological Products
QGENQIAGEN N.V.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

52-Week Range

Low$393.61

High$615.00